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ercutaneous Mitral
alve Repair With the
dge-to-Edge Technique
Surgeon’s Perspective*
awrence H. Cohn, MD, FACC
oston, Massachusetts
he paper by Feldman et al. (1) in this issue of the Journal
s the first published report about a new percutaneous mitral
alve technology, the edge-to-edge Evalve clip (Evalve Inc.,
enlo Park, California). This is an important step into a
ew era of catheter-based valve procedures and one that will
e compared and contrasted with the ongoing excellent
urgical results obtained with mitral valve repair of the
yxomatous regurgitant mitral valve. The investigators,
ho are among the leading cardiac interventionalists in the
ountry, have performed a carefully thought out phase I
.S. Food and Drug Administration safety trial of 27
ow-risk patients with myxomatous valve disease, a group of
atients for whom surgical repair of the mitral valve is safe
See page 2134
nd effective. They have clearly documented the safety of
his procedure, and have also documented that there is a
ignificant learning curve as it relates to fluoroscopy time,
chocardiography time, and anesthesia time. The investiga-
ors have been careful to point out that this device and
imilar devices mandate multi-specialty collaboration, in-
luding cardiac surgery, echocardiography, and cardiac an-
sthesia for patient safety. The interactive nature of this
roject is in compliance with the recent simultaneous
ublication of a position paper of the Society of Thoracic
urgeons, American Association for Thoracic Surgery, and
he Society for Cardiovascular Angiography, endorsed by
he American College of Cardiology Foundation and the
merican Heart Association, regarding percutaneous heart
alve technology and the methods for investigation (2).
The results of this study are encouraging, but several
atients did not have the Evalve device implanted when
ntra-procedure echocardiography failed to show reduction
n mitral regurgitation (MR), there was device detachment
n three patients, and open valve repair or replacement was
equired shortly after implantation in an additional three
atients. The investigators were appropriately conservative
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ifesciences, St. Jude Inc., and Medtronic, Inc.n indicating that a significant number, but clearly not all
atients, achieved reduction of MR; only 50% of the
riginal cohort of patients reached 2 MR or less at six
onths. Feasibility and safety have been answered, but
dditional follow-up planned for the phase II multi-center
tudy will be important to determine whether this repair is
table over the long term.
Obviously, careful training of even the most experienced
nterventionalist will be required for the use of this and
ther similar devices. The manufacturer of this device, as
ell as manufacturers of other devices beginning trials, will
rovide careful training to limit the use of these devices to
hose who work in experienced valve centers (2). This will
e important for public safety as well as determining,
ventually, which are the best devices for a patient popula-
ion.
Ultimately, the long-term efficacy of these devices will
etermine how widely used these devices will be. The
ontrol group has been the remarkably successful mitral
alve repair of the myxomatous valve series on cardiopul-
onary bypass, minimally invasive with an upper or lower
ini-sternotomy (3,4), robotically (5) and thoracoscopically
6), with superb results. What practicing cardiologists may
ave to balance is the benefit of a percutaneous technique
ith residual mild or moderate MR. We do know that
oderate MR, particularly with ischemic heart disease, is
ssociated with poor long-term survival (7).
Finally, a comment about the edge-to-edge technique
ntroduced by Alfieri et al. (8) on which the Evalve is
onceptually based. This technique has been used for mitral
alve repair as an adjunct technique to standard repair
echniques, but when used, it has been in conjunction with
prosthetic annuloplasty ring. In most patients with myx-
matous valve degeneration, the annulus is very deformed.
he remolding annuloplasty ring, developed by Carpentier
9) and Revuelta et al. (10), pioneers in this field, are equally
s important for successful long-term mitral valve repair as
he leaflet repair techniques themselves.
This article is significant for alerting the cardiologic
ublic that there are also a number of other new devices in
evelopment for percutaneous valve technology by several
edical device companies. Different approaches for mitral
alve repair include coronary sinus stenting and annular
tabilization. More problematic, in this observer’s opinion,
re devices for percutaneous aortic valve replacement, given
he type of end-stage patient in whom this will be used for
evere calcific aortic stenosis. The track record of these
evices so far in European trials has been only slightly
romising, with high mortality because of the patient
ubstrate, and the inability to take away calcific debris, to
rotect the coronary arteries, and to prevent severe perival-
ular leaks. Other interesting devices on the horizon may
nclude operative intervention of catheter-based valves on
he beating, working heart. Whatever the approach, these
rials need to ensure careful scrutiny by the U.S. Food and
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Editorial Comment December 6, 2005:2141–2rug Administration, industry, interventionalists, and car-
iac surgeons so that public safety is ensured and the best
perations and devices are developed for the appropriate
atient.
Although we are encouraged by the use of this truly
inimally invasive non-operative treatment of myxomatous
itral valve regurgitation, we obviously need further data
elated to the efficacy and impact of residual MR on long-term
atient prognosis, which will be studied in phase II. The
nvestigators are to be congratulated for carrying out this
nique pilot phase study carefully, safely, and objectively.
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ivision of Cardiac Surgery, Brigham and Women’s Hospital, 75
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